Bausch Health Companies Inc. reported a notable financial performance for the third quarter of 2025, with revenues reaching $2.681 billion, a 7% increase from $2.510 billion in the same period last year. The growth was primarily driven by higher volumes and improved net realized pricing across its Bausch + Lomb, Salix, and Solta Medical segments. Operating income also saw a significant rise, climbing to $619 million from $318 million year-over-year, reflecting a $301 million increase. The net income attributable to Bausch Health was $179 million, a substantial turnaround from a net loss of $85 million in the prior year.
For the nine months ending September 30, 2025, total revenues increased by 6% to $7.470 billion compared to $7.066 billion in 2024. This growth was attributed to higher volumes, improved pricing, and incremental sales from acquisitions. Operating income for the nine-month period rose to $1.339 billion from $988 million, while net income attributable to the company was $269 million, compared to a loss of $139 million in the same period last year. The company’s earnings per share for the quarter were $0.48, compared to a loss of $0.23 in the previous year.
Strategically, Bausch Health has been active in acquisitions, including the purchase of DURECT Corporation for $84 million, which is expected to enhance its pipeline with Larsucosterol, a drug candidate for alcohol-associated hepatitis. The company also acquired Whitecap Biosciences and Elios Vision, further expanding its product offerings in the ophthalmology and glaucoma treatment markets. Additionally, Bausch + Lomb has been focusing on enhancing its manufacturing capabilities, with plans to acquire manufacturing equipment in Mexico.
Operationally, Bausch Health reported a total of 370,516,926 common shares outstanding as of October 24, 2025. The company has been actively managing its capital structure, successfully refinancing significant portions of its debt, which has extended maturities and reduced short-term cash requirements. As of September 30, 2025, the company’s total liabilities were $26.468 billion, down from $26.845 billion at the end of 2024, indicating a strategic focus on improving its financial health.
Looking ahead, Bausch Health remains committed to its B+L Separation strategy, which aims to create two independent entities focused on their respective core businesses. The company is optimistic about its future growth prospects, driven by its diversified product portfolio and ongoing investments in research and development. However, it acknowledges potential risks, including the impact of generic competition and ongoing litigation, which could affect its financial performance.
About Bausch Health Companies Inc.
Bausch Health Companies Inc. is a global specialty pharmaceutical and medical device company focused on gastroenterology, hepatology, neurology, dermatology, and eye health through its majority-owned Bausch + Lomb subsidiary. It develops, manufactures, and markets branded, generic, and OTC pharmaceuticals, aesthetic medical devices, and eye care products across approximately 90 countries. The company leverages a diversified portfolio, extensive R&D, and a broad commercial footprint targeting healthcare providers, patients, and consumers worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.